---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020404"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T12:45:07.998824+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M

## Summary
- FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).
- Net loss attributable to common shareholders FY 2024 $122.8M ($2.49/sh) vs $107.6M ($2.21/sh) in FY 2023.
- Commercial Cell & Gene therapy revenue grew 20% YoY to $25.9M in FY 2024.
- Adjusted EBITDA negative $15.1M in FY 2024 vs negative $8.3M in FY 2023.
- FY 2025 revenue guidance $240M-$250M; gross margin improved to 45.8% in Q4 2024.

## SEC filing metadata
- accession: 0001104659-25-020404
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/0001104659-25-020404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/tm258273d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020404
- JSON: https://secwatch.observer/filing/0001104659-25-020404.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.